Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency
Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency
复制标题
DOI：
10.1016/j.amjcard.2006.11.060
复制
发表时间：
2007-04-15
影响因子：
2.8
通讯作者：
Lytle, Bruce
中科院分区：
文献类型：
--
作者：
Ellis, Stephen G.;Chen, Michael S.;Lytle, Bruce
在美国，每年有近35万名患者继续使用隐静脉移植物作为冠状动脉搭桥手术的导管。基因对SVG寿命的可能贡献尚未得到很好的研究。我们分析了155例患者（2.1 SVGs/患者）中150个候选基因的168个单核苷酸多态性，这些患者接受了10 +/- 4年的临床适应症冠状动脉造影。冠状动脉搭桥术患者年龄为54±8岁，61%为男性，39%为糖尿病患者。在研究开始时，76%的人服用他汀类药物。主要研究终点SVG通畅（直径< 70%狭窄，无干预），5年时为60%，10年时为19%。校正与SVG通畅相关的其他因素（男性，p = 0.007；低密度脂蛋白，p = 0.016）后，5个基因中有7个多态性与SVG通畅相关（p < 0.01）。总之，这些数据代表了使用个性化遗传方法进行冠状动脉血管重建术的第一步。(c) 2007爱思唯尔公司版权所有。
Saphenous veins grafts (SVGs) continue to be used as conduits for coronary bypass surgery in nearly 350,000 patients annually in the United States. A possible genetic contribution to SVG longevity has not been well studied. We analyzed 168 single nucleotide polymorphisms from 150 candidate genes in 155 patients (2.1 SVGs/patient) followed for 10 +/- 4 years who underwent coronary angiography for clinical indications. Age at coronary bypass was 54 +/- 8 years, 61% were men, and 39% had diabetes mellitus. At the time of study entry, 76% were on statins. SVG patency (< 70% diameter stenosis, no intervention), the primary study end point, was 60% at 5 years and 19% at 10 years. After adjustment for other factors associated with SVG patency (male gender, p = 0.007; low low-density lipoprotein, p = 0.016), 7 polymorphisms in 5 genes were associated with SVG patency (p < 0.01). In conclusion, these data represent an initial step toward the use of a personalized genetic approach to coronary revascularization. (c) 2007 Elsevier Inc. All rights reserved.